Regeneron Pharmaceuticals (REGN) Earnings Analysis

Regeneron Pharmaceuticals (REGN) next reports earnings on 2026-07-30, consensus EPS 10.21 USD. Last quarter (2026-01-30) it beat with EPS 11.44 USD vs 10.74 USD est (+6.5%). It has beaten estimates in 4/4 recent quarters (100%). Trailing P/E 15.31.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does REGN next report earnings?

Next earnings date2026-07-30
Consensus EPS estimate10.21 USD
Revenue estimate3.81B

REGN earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-01-3011.44 USD10.74 USD+6.5%Beat
2025-08-0112.89 USD8.43 USD+52.9%Beat
2024-10-3112.46 USD11.69 USD+6.6%Beat
2024-08-0111.56 USD10.61 USD+9%Beat

Beat rate: 4/4 (100%) over reported quarters with consensus data.

REGN valuation and analyst view

Trailing P/E15.31
Trailing EPS42.533 USD
Price / book2.16
Dividend yield0.56%
Market cap67.05B
Analyst consensusBuy (34 buy / 15 hold / 0 sell)
Avg price target815 USD

Related research pages

Frequently asked questions

When is Regeneron Pharmaceuticals (REGN)'s next earnings date?

Regeneron Pharmaceuticals is next scheduled to report on 2026-07-30, with a consensus EPS estimate of 10.21 USD and revenue estimate of 3.81B.

Did REGN beat earnings last quarter?

In its 2026-01-30 report, REGN posted EPS of 11.44 USD versus a 10.74 USD estimate — a beat of 6.5%.

What is REGN's earnings track record?

Over the last 4 reported quarters with consensus data, REGN beat estimates 4 times (100%).

What is REGN's current P/E ratio and EPS?

REGN trades at a trailing P/E of 15.31 on trailing EPS of 42.53269230769231 USD.

What do analysts rate REGN?

Analyst consensus is "Buy" across 49 ratings (0 strong buy, 34 buy, 15 hold, 0 sell, 0 strong sell). Average 12-month price target: 815 USD.